Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Clinical Study
100%
Immunoglobulin Producing Cell
100%
Multiple Myeloma
100%
Interleukin 2
100%
Cytolysis
100%
Lymphokine Activated Killer Cell
100%
Cytokine
36%
Peripheral Blood Mononuclear Cell
36%
Tumor Necrosis
18%
Infusion
18%
Gamma Interferon
18%
Cell Line
9%
Adverse Effect
9%
Cytotoxicity
9%
Lymphocyte
9%
Minimal Residual Disease
9%
Mononuclear Cell
9%
Bone Marrow Transplantation
9%
Myeloma Cell
9%
Lymphokine
9%
Thymidine
9%
Keyphrases
Multiple Myeloma
100%
Interleukin-2
100%
Cell Lysis
100%
Lymphokine-activated Killer Cells
100%
Malignant Plasma Cells
100%
Peripheral Blood Mononuclear Cells
36%
Tumor Necrosis Factor-α
18%
Lysis
18%
In Vivo Applications
18%
Interferon-γ
18%
Cytotoxicity
9%
Plasma Cells
9%
Peripheral Blood Lymphocytes
9%
Allogeneic Bone Marrow Transplantation
9%
Mononuclear Cells
9%
Natural Killer
9%
Malignant Cells
9%
Cells in Culture
9%
Myeloma Cells
9%
Immunomodulatory Effect
9%
Minimal Residual Disease
9%
Serious Adverse Effects
9%
Multiple Myeloma Patients
9%
Thymidine Uptake
9%
Lymphokine-activated Killers
9%
Killer Activity
9%
Effector Target
9%
Immunology and Microbiology
Immunoglobulin Producing Cell
100%
Interleukin 2
100%
Cytolysis
100%
Multiple Myeloma
100%
Lymphokine Activated Killer Cell
100%
Cytokine
36%
Peripheral Blood Mononuclear Cell
36%
Tumor Necrosis Factor Alpha
18%
Interferon Gamma
18%
Cell Line
9%
Peripheral Blood Lymphocyte
9%
Mononuclear Cell
9%
Cytotoxicity
9%
Bone Marrow Transplantation
9%
Myeloma Cell
9%
Lymphokine
9%